NCT07194863Not yet recruiting
Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD
Source: ClinicalTrials.gov · Last updated 13 Jan 2026
Brief summary (registry, in English)
To evaluate the efficacy of Essential phospholipid versus Betaine HCL/L-Glutamic Acid in MAFLD
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 200 (estimated)
- First submitted
- 19 Sept 2025
- Start date
- 1 Nov 2026
- Primary completion date
- 1 Nov 2026
- Lead sponsor
- Assiut University
- Diseases
- Fatty liver disease (MASLD/MASH)
- NCT number
- NCT07194863
What you commit to
- Study type: Observational
- Planned participants: 200
- From 1 Nov 2026 to the primary completion date, 1 Nov 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Fatty liver patients on treatment by statin derivatives or other medications.
Other illness
- Presence of malignancy.
Age
- Patients aged ≤18 years old.
Other
- Pregnancy.
- Type I DM.
- Fatty liver patients undergone bariatric surgeries
Who the study is looking for
- All patients aged \>18 years old
- diagnosed as fatty liver based on clinical examination, laboratory investigations and imaging techniques.
Age in the registry: 18 years to 60 years · Sex: All · Accepts healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.